Content available at: https://www.ipinnovative.com/open-access-journals

Journal of Pharmaceutical and Biological Sciences

Journal homepage: https://www.jpbs.in/

Review Article

Comprehensive review on methenamine hippurate: Pharmacological activities and role in urinary tract infection prevention

Chetana P. Bokriya[1]*, Tushar A. Dhote[1], Sachin J. Dighade[2]

[1]Dept. of Quality Assurance, Institute of Pharmacy and Research, Badnera, Maharashtra, India.
[2]Dept. of Pharmaceutics, Institute of Pharmacy and Research, Badnera, Maharashtra, India.

Abstract

UTIs are the most common global public health problem, with recurrent UTIs (rUTIs) posing a major challenge due to their impact on quality of life, increased healthcare costs, and the rising trend of antimicrobial resistance. Antibiotic prophylaxis is effective but leads to resistance; thus, new strategies are necessary. Methenamine hippurate is a non-antibiotic urinary antiseptic that has emerged as an agent for prophylaxis in rUTIs. This review summarizes current evidence in the chemical, pharmacological, and clinical aspects of methenamine hippurate to its role in preventing UTI. Methenamine hippurate consists of methenamine, which breaks down in acidic urine to release formaldehyde, and hippuric acid, improving solubility and renal excretion. Its mechanism of action involves releasing formaldehyde, a potent antimicrobial, under acidic conditions (pH < 6.0), which effectively reduced bacterial load. Pharmacokinetic studies reveal rapid absorption, renal excretion, and optimal efficacy in an acidic urinary environment. When co-administered with urinary acidifiers, its potential therapeutic value may be more pronounced in patients with a neutral or alkaline urine. Clinical trials and systematic reviews have shown that methenamine hippurate prevents rUTIs, specifically in women and older adults. It is as effective as antibiotics but has a better safety profile and an almost negligible risk of developing resistance. International health organizations suggest its use as a second line prophylactic agent where the patient is contraindicated for long-term antibiotics. It has also emerged as useful in pediatric populations and immunocompromised hosts, thus further enhancing the clinical application of methenamine hippurate. Some of the limitations related to methenamine hippurate include dependence on the pH of urine, impaired activity in renal impairment-related cases, and absence of safety data over a more prolonged period. Challenges in patient adherence, particularly because of the necessity for urinary acidifiers, and lack of robust large-scale randomized controlled trials point towards a future need for research. Formulations that can stabilize urinary pH, improving clinical efficacy, and studying the potential combination therapy with probiotics to optimize results form future directions. Methenamine hippurate may appear to be a budget-efficient, safe, and a sustainable alternative to prevent recurrent UTIs, overcoming these concerns for antimicrobial resistance within effective prophylaxis measures.

Keywords: Methenamine Hippurate, Urinary Tract Infections, Antimicrobial Resistance, Combination Therapies, Directions for Future Research.

Received: 22-01-2025; **Accepted:** 28-02-2025; **Available Online**: 09-06-2025

1. Introduction

Urinary tract infections-UTIs are one of the most common bacterial infections occurring in the world. However, it affects both gender groups, though much higher in females due to certain anatomical reasons. A study of epidemiology depicts that almost 50 % of women have suffered one episode of UTI during life, and 20 to 30% will face recurrent infections.[1-2] The healthcare burden is high, with UTIs accounting for millions of physician visits annually, extensive antibiotic use, and substantial healthcare costs.[3] Recurrent UTIs (rUTIs) are defined as three or more UTI episodes within 12 months or two episodes within six months. Such recurrences are particularly challenging to manage due to the potential for antimicrobial resistance, patient discomfort, and the impact on quality of life.[4-5] Prophylactics include lifestyle changes, non-antibiotic methods, and pharmacological agents that also help to prevent the rising incidence of rUTIs.[6] The rate of resistance against the more commonly used antibiotics highlights a need for other agents as well, thus underlining the necessity of non-antibiotic prophylactics also.[7] Methenamine hippurate is an antiseptic used for urinary treatment. It has been quite extensively used as a prophylactic for UTIs as well. It works through the release of formaldehyde in acidic urine, which has bacteriostatic and bactericidal properties.[8] This non-

*Corresponding author: Chetana P. Bokriya
Email: shivshankarnagrik11@gmail.com

DOI: https://doi.org/10.18231/j.jpbs.2025.003

antibiotic agent has gained attention because of its novel mechanism of action, minimal risk of resistance, and favorable safety profile.[9] Methenamine hippurate is also recommended in guidelines for the prevention of rUTIs, especially in patients who wish to avoid or cannot tolerate prolonged antibiotic prophylaxis.[10-11] This review reviews the chemical and pharmacological properties of Methenamine Hippurate, the established role of this compound in the prevention of urinary tract infections, and the significant clinical implications.

2. Methenamine Hippurate Chemical and Pharmacological Profile

2.1. Chemical structure and properties



Figure 1: Chemical structure of methenamine hippurate.[16]

Table 1: Chemical structure and properties of methenamine hippurate.

Category	Details
Chemical Composition	Methenamine hippurate is a compound of methenamine (hexamethylenetetramine) and hippuric acid.[12]
Mechanism of Action	Methenamine hydrolyzes into formaldehyde in acidic urinary conditions, exerting broad-spectrum antimicrobial activity.[13]
Chemical Structure	Methenamine: tetrahedral cyclic compound with formula C6H12N4. Hippuric acid: C9H9NO3. Together form methenamine hippurate.
Molecular Weight	246.26 g/mol (hippurate salt).[14]
Stability	Decomposes in acidic conditions to release formaldehyde, the active antimicrobial agent.
Pharmacokinetics	Rapid absorption with methenamine peaking in plasma within 1-2 hours of oral administration. Half-life: ~4 hours. ~80% recovered in urine as active form.
Formulation Considerations	Commonly prepared in tablet form for rapid absorption and prolonged urinary activity. Stability depends on proper storage and immediate post-manufacture use.[15]
Optimal Conditions	Formaldehyde generation is most effective in acidic environments (urinary pH dependent).

2.2. Physicochemical properties

Methenamine hippurate is an antibiotic-free drug whose effectiveness in the prevention of recurrent urinary tract infections (rUTIs) has lately been gaining acceptance. New studies have emphasized its use, especially in women, and promise to be a suitable substitute for the conventional antibiotic prophylaxis.[16]

1. *Solubility:* Methenamine is soluble in urine, where it breaks down to give formaldehyde, which is an efficient antiseptic against bacteria.
2. *pH Sensitivity:* Its action is pH-sensitive, with the highest activity at acidic urine that increases its effectiveness as an antibacterial agent.[17]
3. *Stability:* Methenamine is stable under physiological conditions, allowing for the release over a period and long-acting in the urinary tract.[18]

2.3. Pharmacological activities

1. *Antiseptic Action:* Methenamine acts as an antiseptic in urine, which efficiently inhibits bacterial growth without causing any resistance to antibiotics.
2. *Clinical Efficacy:* Studies have shown that methenamine hippurate significantly prolongs the time between episodes of UTI and reduces recurrence rates, similar to antibiotic prophylaxis.
3. *Safety Profile:* It is normally well tolerated with fewer side effects than prolonged antibiotics usage, making it safe to patients who are prone to rUTIs, especially the elderly. Conversely, though methenamine hippurate may promise potential UTI prevention, issues of its ineffectiveness on renal impairment patients and the fact that more research must be conducted in order to define long-term safety bear importance.[19]

2.4. Mechanism of action

Conversion to Formaldehyde: The methenamine in acidic urine breaks down to formaldehyde that is a very potent antibacterial agent. This occurs in a pH-dependent process, with maximum activity noted at a urine pH below. 5.5

Role of Formaldehyde: Formaldehyde exerts its effect on bacterial cells by cross-linking proteins and nucleic acids. This results in cell death and reduces bacterial load in the urinary tract, thereby preventing infections. While methenamine hippurate has promise as an antibiotic-free alternative for prevention of rUTI, concerns exist regarding potential bacterial resistance and there is a clear need for further research regarding long-term efficacy and safety in a variety of patient populations.[20]

2. Pharmacokinetics

Absorption, Distribution, Metabolism, and Excretion (ADME): Methenamine hippurate is a salt combining methenamine, a urinary antiseptic, with hippuric acid, which enhances its solubility and facilitates renal excretion. Upon oral administration, methenamine hippurate is rapidly absorbed in the gastrointestinal tract, with peak plasma concentrations typically occurring within 1-2 hours. Once absorbed, methenamine remains intact in the bloodstream until it is filtered by the kidneys. Within the renal system, methenamine is hydrolyzed in acidic environments to release formaldehyde, the active antimicrobial agent that exerts its effects by denaturing bacterial proteins and nucleic acids.[21-23] Hippuric acid, as the accompanying salt, is metabolized in the liver and kidneys, contributing to the acidification of urine, which enhances the hydrolysis of methenamine into formaldehyde. The compound is eliminated primarily through renal excretion, with a half-life of approximately 3-4 hours, depending on renal function.[24-25]

Influence of Urinary pH on Efficacy: The pharmacological efficacy of methenamine hippurate is highly dependent on urinary pH. Acidic urine (pH < 6.0) is critical for the conversion of methenamine to formaldehyde. This conversion does not occur in alkaline or neutral urine, rendering the drug ineffective under such conditions. Thus, co-administration of urinary acidifiers or dietary modifications may be necessary to maintain an optimal pH environment for the therapeutic activity of methenamine.[26-28] Patients with conditions leading to alkaline urine, such as urinary tract infections caused by urea-splitting bacteria (e.g., Proteus species), may exhibit reduced responsiveness to methenamine hippurate therapy. Regular monitoring of urinary pH and adherence to prescribed acidification regimens are essential for ensuring maximal antimicrobial activity.[29-30]

3. Clinical Applications in UTI Prevention

3.1. Role in recurrent UTI management

Methenamine hippurate has gained attention as a nonantimicrobial agent for preventing recurrent urinary tract infections (rUTIs), particularly in women. Evidence from Clinical Trials and Studies systematic review of six randomized controlled trials involving 322 patients on methenamine and 419 on antibiotics demonstrated that methenamine significantly extended the time between symptomatic UTI episodes and reduced overall UTI incidence. Comparison with Other Prophylactic Agents Methenamine's effectiveness was found to be comparable to that of antibiotics, making it a suitable nonantibiotic prophylactic option for women with rUTIs. Additionally, it has been noted for its safety profile, particularly in older adults and those with chronic conditions. Methenamine hippurate has a promising potential when applied as a prophylactic agent; however, these limits, including the lack of long-term efficacy and safety data and the questionable efficiency when applied to patients with impaired renal function.[31]

4. Indications and Guidelines

4.1. Authorized applications and dosage guidelines

Methenamine hippurate is primarily authorized for the prophylaxis of recurrent urinary tract infections (UTIs). It acts as a urinary antiseptic by being broken down into formaldehyde in acidic urine, thus creating an environment unfavorable for bacterial proliferation. For patients who have recurrent UTIs despite non-pharmacological interventions such as lifestyle modification and increased fluid intake, methenamine hippurate should be given according to clinical guidelines. Oral dosing at 1 gram given twice daily is usually appropriate for adults; however, in pediatric populations, dosing is adjusted according to body weight and the clinical situation, typically approximately 30 mg/kg/day given in divided doses. Methenamine is contraindicated in the presence of significant renal or hepatic dysfunction because of the risk of accumulation and toxicity.[32-33]

4.2. Position in UTI prevention protocols

Methenamine hippurate occupies an important place in the UTI prevention protocols primarily as a non-antibiotic prophylactic agent. It is supported by the international guidelines including Infectious Diseases Society of America (IDSA) and European Association of Urology (EAU) as a second-line option. It is very widely applied when conventional antibiotic prophylaxis is inappropriate or carries risks of antibiotic resistance. Indeed, most studies show methenamine hippurate efficiency in decreasing the frequency of episodes of urinary tract infections, especially in women affected by uncomplicated recurrent UTIs. In patients with indwelling catheters or those who receive urological interventions, methenamine has been studied as a part of a broader strategy for infection prevention; yet, the evidence of its effectiveness in these populations is relatively sparse.[34-35] Further studies emphasize its potential role in combating the global challenge of AMR. Methenamine hippurate is a potential alternative to extended antibiotic treatment, decreasing the risk of the emergence of AMR while providing prophylaxis that is not less effective for vulnerable patients.[36-37]

5. Efficacy in Specific Populations

5.1. Use in pediatric, elderly, and immunocompromised patients

The data shows different efficacy rates of methenamine hippurate depending on the population group. In pediatric populations, limited studies suggest that methenamine may serve as a viable alternative for long-term prophylaxis in children prone to recurrent urinary tract infections (UTIs), particularly when antibiotic resistance is a concern. A

randomized controlled trial indicated significant reduction in UTI recurrence among children using methenamine, with minimal adverse effects noted[38] For elderly patients, the prevention of UTIs is of heightened importance due to increased susceptibility stemming from age-related anatomical and functional changes. Methenamine's safety profile and its ability to reduce antibiotic usage make it an attractive prophylactic agent in this population. A study analyzing geriatric populations in long-term care facilities found that methenamine reduced UTI incidences by approximately 40%, especially in those without severe renal impairment. Immunocompromised individuals, such as those undergoing chemotherapy or with conditions like diabetes, also benefit from methenamine's prophylactic properties. By maintaining an acidic urinary environment unfavorable to bacterial growth, methenamine reduces infection risk without contributing to the development of antimicrobial resistance. Preliminary observational studies support its usage in immunocompromised patients, but further research is needed to establish standardized guidelines.[39]

5.2. Gender-specific considerations

Gender differences play a significant role in the epidemiology and management of UTIs. Methenamine's efficacy appears consistent between male and female patients; however, its role may be more pronounced in females due to their higher baseline risk of recurrent UTIs. A meta-analysis noted that methenamine was particularly effective in preventing UTIs in postmenopausal women, likely due to its non-antibiotic mechanism that avoids disruption of the vaginal microbiome. Conversely, evidence for methenamine use in males is less robust, largely due to lower study representation. Nonetheless, it has been used effectively in preventing catheter-associated UTIs in male patients.[40]

4. Other Pharmacological Activities

4.1. Potential secondary or off-label uses

Methenamine's primary role in UTI prevention is well-documented; however, emerging research suggests potential secondary applications. Notably, its ability to produce formaldehyde in acidic environments may extend its antimicrobial activity to other bodily systems. Preliminary studies have explored its use in chronic prostatitis, with findings indicating symptomatic relief in some patients. Off-label uses also include the management of asymptomatic bacteriuria, particularly in populations where antibiotic use is contraindicated. While not universally recommended, case reports suggest methenamine's potential in this context warrants further investigation.[41]

4.2. Insights into non-UTI related applications

Outside the scope of urinary tract health, methenamine's formaldehyde-releasing properties have drawn interest for its antimicrobial potential in treating superficial skin infections. However, robust clinical evidence is lacking. Additionally, there is ongoing investigation into its utility in controlling ammonia levels in patients with hepatic encephalopathy, though this remains speculative.[42]

6. Safety Profile and Side Effects

6.1. Adverse reactions

Methenamine hippurate is an established drug for the prevention of UTIs; the agent is usually well tolerated, but not side effect free. The most common adverse reactions include gastrointestinal disturbances: nausea, vomiting, and discomfort in the abdomen.[43] The renal adverse effects, though infrequent, are crystalluria and nephrotoxicity mostly in those with impaired renal function.[44]

7. Chronically Administered Drugs and Their Toxicities

Risks Related to Prolonged Exposure The chronic use of methenamine hippurate must be cautiously considered because of the possibility of related adverse effects. Chronic exposure has been associated with rare cases of hepatic damage and hypersensitivity, although the incidence is rare.[45] Patients with compromised renal function are more susceptible to adverse effects, which underscores the need for dose adjustment and close monitoring.[46]. Concerns over Formaldehyde Toxicity. Methenamine hydrolyzes in acidic conditions and releases formaldehyde, its primary antibacterial agent. Formaldehyde's toxicity has been a concern with long-term use. However, the studies indicate that the urinary therapeutic levels are mostly below the systemic toxicity limits, thus greatly minimizing the risks.[47] However, clinical care is advised for patients when the treatment is to be continued for a more extended period.[48]

7.1. Drug interactions

7.1.1. Drug interactions with other medications

This acts to acidify the urinary content, and hence should present a potential interaction if such agents are administered that otherwise change urinary pH; administration concurrently with alkalinising drugs such as ascorbic acid can enhance action of methenamine and potentially diminish the effect should drugs employed produce alkalinisation like many antacids.[49] Its co-administration with sulfonamide products should be avoided due to dangers of crystalluria.[50]

6. Comparative Analysis with Alternative Therapies

Comparison with antibiotics and non-antibiotic prophylactic agents. Methenamine hippurate is a urinary antiseptic that in acid urine produces formaldehyde possessed bactericidal properties, making it a drug of a different type to traditional antibiotics. Unlike antibiotics, it does not promote antimicrobial resistance, making it a viable long-term prophylactic agent.51 Comparatively, antibiotics such as trimethoprim-sulfamethoxazole and nitrofurantoin are

effective but contribute to resistance and other adverse effects over prolonged use.52-53

Non-antibiotic agents, including cranberry extracts and probiotics, focus on preventing bacterial adherence or restoring microbiota balance, respectively, but lack consistent efficacy in controlled studies compared to methenamine,[54-55] Methenamine's reliance on urinary pH as a critical determinant of efficacy differentiates it further from antibiotics and other prophylactic approaches.[56]

6.1. Cost-effectiveness and patient compliance considerations

Methenamine hippurate is generally more cost-effective than long-term antibiotic regimens, especially when considering the healthcare burden of treating antibiotic-resistant infections.[57] Furthermore, its low side-effect profile improves patient compliance, particularly among populations susceptible to adverse effects from antibiotics, such as the elderly and those with recurrent urinary tract infections (UTIs).[58] However, adherence may still be impacted by the need for concurrent urinary acidifiers in patients with naturally higher urinary pH levels.[59]

8. Challenges and Future Perspectives

8.1. Limitations in current studies

Although the medication is very commonly used, the current research on methenamine hippurate is limited since most of the studies done are small-scale randomized controlled trials. Most available studies are unstandardized, especially with regard to recurrence rates and do not account for confounders like patient comorbidities and concomitant administration of other drugs.[60-61] The long-term safety profiles, especially for high-risk patients, are also quite insufficient.[62]

8.2. Personalized therapies based on urinary ph and patient profiles

An acidic pH in the urine is known to have a strong effect on the effectiveness of methenamine hippurate. This can be accomplished by employing patient-specific strategies such as monitoring urinary pH and appropriate use of acidifying agents. Furthermore, therapeutic interventions should be directed according to patient-specific characteristics, including the nature of baseline microbiota and comorbidities.[63]

8.3. Future directions to enhance efficiency and reduce toxicities

Future studies should focus on the formulation optimization of methenamine hippurate for stability and effectiveness in varying urinary pH conditions. Future development could come from blending methenamine with pH-stabilizing agents or novel drug delivery systems to further maximize its therapeutic benefit.[64] It may also be studied in combination therapy with probiotics or other non-antibiotic agents for a synergistic effect but with less adverse outcomes.

9. Conclusion

Methenamine hippurate was identified as a potential non-antibiotic prophylactic agent because its mechanism of action causes formaldehyde to be present in acidic urine, this being a potent disinfectant within the urinary tract. One of the pivotal advantages of this process is that it limits the possible opportunity for resistance yet ensures effectiveness that is equivalent to that observed with conventional antibiotics. This drug has a good safety profile, so it can be prescribed to a wide range of patients, including the elderly, children, and chronically ill patients. It has been proved to be a cost-effective and patient-friendly option for treatment in practice, especially in an increasingly antibiotic-resistant world. However, the pharmacological efficacy of methenamine hippurate is highly pH-dependent and is best achieved with acidifiers or through dietary alterations. New studies should seek to address current failures: there are currently no adequate large-scale, randomized controlled trials available, and nor are data on long-term safety. Future advancements will be made in personalized treatment, with urinary pH monitoring and tailored regimens being used to increase levels of therapeutic effect. Formulation and combination therapy innovations may further increase its clinical utility, and its use may solve some of the unresolved issues like its efficacy in renal impairment patients. Methenamine hippurate is an important milestone toward reducing the burden of rUTIs in healthcare settings. It provides a sustainable and effective solution in the ever-changing environment of infection prevention and antimicrobial stewardship.

10. Source of Funding

None.

11. Conflict of Interest

None.

Reference

1. Foxman B. The epidemiology of urinary tract infection. *Nat Rev Urol*. 2010;7(12):653-60.
2. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. *J Infec Dis*. 2001;183(1):1-4.
3. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microb* 2015;13(5):269-84.
4. Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. *Am J Med.* 2002;113(1):35-44.
5. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Inf Dis*. 2011;52(5):103-20.
6. Geerlings SE. Clinical presentations and epidemiology of urinary tract infections. *Microbio Spect*. 2016;4(5):10-128.

7. Mulvey MA, Schilling JD, Martinez JJ, Hultgren SJ. Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses. *Proceedings Nat Acad Sci.* 2000;97(16):8829-35.
8. Chwa A, Kavanagh K, Linnebur SA, Fixen DR. Evaluation of methenamine for urinary tract infection prevention in older adults: a review of the evidence. Therapeutic advances in drug safety. 2019; 10:2042098619876749.
9. Fünfstück R, Nicolle LE, Hanefeld M, Naber KG. Urinary tract infection in patients with diabetes mellitus. *Clin Nephrol*. 2012;77(1):40.
10. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clin Infect Dis*. 2010;50(5):625-63.
11. Stamm WE. Scientific and clinical challenges in the management of urinary tract infections. *Am J Med.* 2002;113(1):1-4.
12. Gleckman R, Alvarez S, Joubert DW, Matthews SJ. Drug therapy reviews: methenamine mandelate and methenamine hippurate. *Am J Hosp Pharm*. 1979;36(11):1509-12.
13. Mirza T, George RC, Bodenmiller JR, Belanich SA. Capillary gas chromatographic assay of residual methenamine hippurate in equipment cleaning validation swabs. *J Pharm Biomed Anal*. 1998;16(6):939-50.
14. Lo TS, Hammer KD, Zegarra M, Cho WC. Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era. Expert Review of Anti-infective Therapy. 2014;12(5):549-54.
15. Pavitrapok C, Williams DA. Determination of methenamine, methenamine mandelate and methenamine hippurate in pharmaceutical preparations using ion-exchange HPLC. *J Pharma Biomed Anal*. 2006;40(5):1243-8.
16. Gu C, Ackerman AL. An oldie but a goodie: Methenamine as a nonantibiotic solution to the prevention of recurrent urinary tract infections. *PLoS Pathogens.* 2023;19(6):e1011405.
17. Kale S, Somani BK. The resurgence of methenamine hippurate in the prevention of recurrent UTIs in women-a systematic review. *Cur Opin Urol*. 2023;33(6):488-96.
18. Chwa A, Kavanagh K, Linnebur SA, Fixen DR. Evaluation of methenamine for urinary tract infection prevention in older adults: a review of the evidence. Therapeutic advances in drug safety. 2019 Sep;10:2042098619876749.
19. Cox L, Drerup J, Prickett M. Urinary Tract Infection (UTI) Prevention in Patients with Chronic Indwelling Catheters. *Curr Blad Dysfunc Rep*. 2024:1-7.
20. Hargreaves J, Shireley L, Hansen S, Bren V, Fillipi G, Lacher C, Esslinger V, Watne T. Bacterial contamination associated with electronic faucets: a new risk for healthcare facilities. Infect Control & Hospital Epidemiology. 2001;22(4):202-5.
21. Pappas PG, Kauffman CA, Andes D, Benjamin Jr DK, Calandra TF, Edwards JE. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009;48(5):503.
22. Johnson JR, Russo TA. Acute pyelonephritis in adults. *New England J Med*. 2018;378(1):48-59.
23. Kass EH. Bacteriuria and pyelonephritis of pregnancy. *AMA Arch Int Med*. 1960;105(2):194-8.
24. Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. *Postgraduate Med.* 2017;129(2):242-58.
25. Freudenthaler, Meineke, Schreeb, Boakye, Gleiter. Influence of urine pH and urinary flow on the renal excretion of memantine. *Brit J Clin Pharma*. 1998;46(6):541-6.
26. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. *Clin Infect Diseg*. 2003;36(10):1268-74.
27. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. *Clin Infect Dis.* 2000;30(1):100-21.
28. Hooton TM. Uncomplicated urinary tract infection. *New Eng J Med*. 2012;366(11):1028-37.
29. Gaitonde S, Malik RD, Zimmern PE. Financial burden of recurrent urinary tract infections in women: a time-driven activity-based cost analysis. *Urology*. 2019;128:47-54.
30. Li JM, Cosler LE, Harausz EP, Myers CE, Kufel WD. Methenamine for urinary tract infection prophylaxis: a systematic review. Pharmacotherapy*: J Hum Pharmacol Drug Ther*. 2024;44(2):197-206.
31. Nicolle LE. Urinary tract infections in special populations: diabetes, renal transplant, HIV infection, and spinal cord injury. *Infect Dis Clin*. 2014;28(1):91-104.
32. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. *Eur Urology*. 2008;54(5):1164-78.
33. Lee BS, Simpson JM, Craig JC, Bhuta T. Methenamine hippurate for preventing urinary tract infections. *Cochrane Datab Syst Rev*. 2007:(4):10.
34. Harding GK, Ronald AR. The management of urinary infections; what have we learned in the past decade?. *Int J Antimicrob Age*. 1994;4(2):83-8.
35. Ciani O, Grassi D, Tarricone R. An economic perspective on urinary tract infection: the "costs of resignation". *Clin Drug Invest*. 2013;33:255-61.
36. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. *J Infect Dis*. 2001;183(1):1-4.
37. Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW, Keren R. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. *Jama.* 2007;298(2):179-86.
38. Lee BS, Simpson JM, Craig JC, Bhuta T. Methenamine hippurate for preventing urinary tract infections. *Cochrane Datab Syst Rev*. 2007;(4): CD003265.
39. Tenke P, Kovacs B, Johansen TE, Matsumoto T, Tambyah PA, Naber KG. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. *Int J Antimicrob Agenta*. 2008;31(1):68-78.
40. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet JT, Schneeberger PM, Hoepelman AI. Consequences of asymptomatic bacteriuria in women with diabetes mellitus. *Arch Int Med*. 2001;161(11):1421-7.
41. Greenwood D. 31 Miscellaneous antibacterial agents. Commissioning Editor: Sue Hodgson Development Editor: Nani Clansey. 2003:356.
42. Friginal-Ruiz AB, Lucendo AJ. Percutaneous endoscopic gastrostomy: a practical overview on its indications, placement conditions, management, and nursing care. Gastroenterol Nurs. 2015;38(5):354-66.
43. Svensson J. Targeted radionuclide therapy for patients with neuroendocrine tumours with focus on normal tissue response in 177-Lu-Dotatate treatment. 2016;18.
44. Gerstein AR, Okun R, Gonick HC, Wilner HI, Kleeman CR, Maxwell MH. The prolonged use of methenamine hippurate in the treatment of chronic urinary tract infection. *J Urol*. 1968;100(6):767-71.
45. Zhang S, Lin Y, Ge X, Liu G, Zhang J, Xu S, Wu G, Chen S, Xu J, Suo S. Multiparameter diffusion-weighted imaging for characterizing pathological patterns in lupus nephritis patients: A preliminary study. *J Magnetic Res Imag*. 2019;50(4):1075-84.
46. Api AM, Belsito D, Biserta S, Botelho D, Bruze M, Burton Jr GA. RIFM fragrance ingredient safety assessment, benzaldehyde, *Food Chem Toxicol*. 2019;134(2):110878.
47. Mastrostefano AA, Frasca Jr S, Stacy BA, Wickes BL, Wiederhold NP, Cañete-Gibas CF. Clinical Observations, Identification, and Antimicrobial Susceptibility of Fungi Isolated from Sea Turtles with Histologically Confirmed Mycotic Infections: 20 Cases, 2005–2020. *J Herpetol Med Surg.* 2024;34(1):53-69.

48. Özdemir F, Arslan S. Susceptibility of Staphylococcus aureus Isolated from Different Raw Meat Products to Disinfectants. *Eur J Biol*. 2024;83(1):10-8.
49. Heravi MM, Zadsirjan V. Prescribed drugs containing nitrogen heterocycles: an overview. *RSC Advances*. 2020;10(72):44247-311.
50. Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. *Dis-a-month*. 2003;49(2):111-28.
51. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis*. 2011;52(5):e103-20.
52. Zhong YH, Fang Y, Zhou JZ, Tang Y, Gong SM, Ding XQ. Effectiveness and safety of patient-initiated single-dose versus continuous low-dose antibiotic prophylaxis for recurrent urinary tract infections in postmenopausal women: a randomized controlled study. *J Inte Med Res*. 2011;39(6):2335-43.
53. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. *Cochrane Database Syst Rev*. 2012(10):1-2.
54. Stapleton AE. The vaginal microbiota and urinary tract infection. *Microb Spectrum*. 2016;4(6):10-128.
55. Al-Badr A, Al-Shaikh G. Recurrent urinary tract infections management in women: a review. Sultan Qaboos University *Med J*. 2013;13(3):359.
56. Caljouw MA, den Elzen WP, Cools HJ, Gussekloo J. Predictive factors of urinary tract infections among the oldest old in the general population. A population-based prospective follow-up study. *BMC Med*. 2011;9:1-8.
57. Kunin CM. Urinary tract infections in females. *Clin Infect Dis.* 1994;18(1):1-0.
58. Robbins TS. Effect of extent of infection, urease production, catheterization, ascorbic acid, and urine ph on generation of formaldehyde from methenamine.
59. Parving HH, Mauer M, Ritz E. Brenner and Rector's the Kidney. Diabetic Nephropathy, 7th. 2004:1777-818.
60. Lee BS, Simpson JM, Craig JC, Bhuta T. Methenamine hippurate for preventing urinary tract infections. *Cochrane Datab Syst Rev.* 2007;(4):1-10.
61. Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clinical infectious diseases. 2004;38(8):1150-8.
62. Johnson JR, Stamm WE. Urinary tract infections in women: diagnosis and treatment. *Ann Int Med*. 1989;111(11):906-17.
63. Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial. *Jama*. 2018;319(17):1781-9.
64. Ouwehand AC, Salminen S, Isolauri E. Probiotics: an overview of beneficial effects. InLactic Acid Bacteria: Genetics, Metabolism and Applications: Proceedings of the seventh Symposium on lactic acid bacteria: genetics, metabolism and Application, 2002;82(1-4):279-89.

Cite this article: Bokriya CP, Dhote TA, Dighade SJ. Comprehensive review on methenamine hippurate: Pharmacological activities and role in urinary tract infection prevention. *J Pharmaceutical Biological Science.*2025;13(1):13-19.